ES2225789T3 - Empleo de derivados de triptofano para el tratamiento citostatico especifico de tumores productores de serotonina. - Google Patents

Empleo de derivados de triptofano para el tratamiento citostatico especifico de tumores productores de serotonina.

Info

Publication number
ES2225789T3
ES2225789T3 ES02732330T ES02732330T ES2225789T3 ES 2225789 T3 ES2225789 T3 ES 2225789T3 ES 02732330 T ES02732330 T ES 02732330T ES 02732330 T ES02732330 T ES 02732330T ES 2225789 T3 ES2225789 T3 ES 2225789T3
Authority
ES
Spain
Prior art keywords
htp
tryptophan
serotonin
tumors
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02732330T
Other languages
English (en)
Spanish (es)
Inventor
Diego Walther
Michael Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Application granted granted Critical
Publication of ES2225789T3 publication Critical patent/ES2225789T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
ES02732330T 2001-03-15 2002-03-15 Empleo de derivados de triptofano para el tratamiento citostatico especifico de tumores productores de serotonina. Expired - Lifetime ES2225789T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10112882A DE10112882A1 (de) 2001-03-15 2001-03-15 Verwendung von Tryptophan-Derivaten zur spezifischen zytostatischen Behandlung von Serotonin-produzierenden Tumoren
DE10112882 2001-03-15

Publications (1)

Publication Number Publication Date
ES2225789T3 true ES2225789T3 (es) 2005-03-16

Family

ID=7677818

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02732330T Expired - Lifetime ES2225789T3 (es) 2001-03-15 2002-03-15 Empleo de derivados de triptofano para el tratamiento citostatico especifico de tumores productores de serotonina.

Country Status (7)

Country Link
US (2) US20040097576A1 (https=)
EP (1) EP1368027B1 (https=)
JP (1) JP2004519500A (https=)
AT (1) ATE272400T1 (https=)
DE (2) DE10112882A1 (https=)
ES (1) ES2225789T3 (https=)
WO (1) WO2002074309A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043124A1 (de) * 2000-08-31 2002-03-14 Max Delbrueck Centrum Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase
GB2409048B (en) 2003-12-09 2007-07-11 Peter Steven Robertson Electricity metering
US20060264178A1 (en) * 2005-05-20 2006-11-23 Noble Gayle L Wireless diagnostic systems
CN109912489B (zh) * 2019-03-08 2022-05-13 哈尔滨商业大学 非活化烯烃烷基化合成2,3-二氢色胺类化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2236876C3 (de) * 1971-08-19 1981-02-12 Ajinomoto Co., Inc., Tokio N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel
US4183858A (en) * 1977-07-01 1980-01-15 Merrell Toraude Et Compagnie α-Vinyl tryptophanes
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US5631281A (en) * 1989-06-29 1997-05-20 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
WO2003030907A1 (en) * 2001-10-09 2003-04-17 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto

Also Published As

Publication number Publication date
DE50200757D1 (de) 2004-09-09
ATE272400T1 (de) 2004-08-15
US20070299128A1 (en) 2007-12-27
WO2002074309A2 (de) 2002-09-26
US20040097576A1 (en) 2004-05-20
EP1368027B1 (de) 2004-08-04
JP2004519500A (ja) 2004-07-02
EP1368027A2 (de) 2003-12-10
DE10112882A1 (de) 2002-09-19
WO2002074309A3 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
Tegeder et al. Inhibition of NF-kappaB and AP-1 activation by R-and S-flurbiprofen
Ahmad et al. [32] Mechanism of photodynamic therapy-induced cell death
DK1206261T3 (da) Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
BR9710686A (pt) Método de tratamento de tumores malignos com tiroxinas análogas não possuindo atividade hormonal siginificativa.
Berger et al. Ethylene glycol and amino acid derivatives of 5-aminolevulinic acid as new photosensitizing precursors of protoporphyrin IX in cells
Poylin et al. The NF‐κB inhibitor curcumin blocks sepsis‐induced muscle proteolysis
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2001054681A8 (en) Composition for treatment of stress
JPH10245337A (ja) 薬学的組成物
Fiorucci et al. NO-aspirin: mechanism of action and gastrointestinal safety
RU94026283A (ru) Фармацевтическое соединение
CN1997361A (zh) 抗肿瘤药物
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
CA2227238C (en) Method of treating colonic adenomas
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
PL342614A1 (en) Anticarcinogenic drugs
ES2225789T3 (es) Empleo de derivados de triptofano para el tratamiento citostatico especifico de tumores productores de serotonina.
WO2006084197A2 (en) Nitroxides for use in treating or preventing neoplastic disease
US8609677B2 (en) Molecules for the photodynamic treatment of tumors and hyperplasias
JP2000513031A (ja) 癌治療の為のＨＭＧ ＣｏＡレダクターゼ阻害剤との組合せに於けるファルネシルトランスフェラーゼ阻害剤
Granik et al. Nitric oxide synthase inhibitors: biology and chemistry
US20050038115A1 (en) Helianthrone derivatives as anti-cancer agents
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók
RU2002116408A (ru) Способ реперфузионной терапии больных острым инфарктом миокарда